Skip to main content

Therapeutic Proteins and Oral Vaccines Market Growth Opportunities, Driving Factors by Manufacturers, Regions, Type and Application, Forecast Analysis to 2028

 


The global therapeutic proteins and oral vaccines market size is estimated to be valued at US$ 201,042.7 million in 2020 and is expected to exhibit a CAGR of 6.7% over the forecast period (2020-2027).

The increasing investments by key players for the development of promising therapies for treatment of different disease conditions is expected to drive the market growth over the forecast period. For instance, in March 2020, research scientists at Migal Galilee Research Institute Ltd, the research and development center of MigVax Ltd, announced to develop a oral vaccine for a deadly coronavirus virus affecting poultry could be adapted for human use against the novel coronavirus known as 2019-nCoV and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Moreover, increasing prevalence of oncology disease is expected to drive growth of the global therapeutic proteins and oral vaccines market. For instance, according to the World Health Organization report published in September 2018, cancer is the second leading cause of death globally, with around 70% of deaths occurring in low and middle income countries.

Global Therapeutic Proteins and Oral Vaccines Market- Impact of Coronavirus (Covid-19) Pandemic

The increasing prevalence of COVID-19 has caused production factories to shutdown in almost all sectors, and also affected the supply of raw materials and Active Pharmaceutical Ingredients (API) of the manufacturing companies across the globe. Moreover, various guidelines have been implemented by regulatory authorities for manufacturing of active pharmaceutical ingredients and pharmaceutical products to avoid the spread of COVID-19 and also to reduce the contamination of active pharmaceutical ingredients during the manufacturing process of pharmaceuticals products such as vaccines, tablets, and others.

According to the U.S. Food Drug and Administration’s report of June 2020, owing to the COVID-19 public health emergency, drug manufacturers are required to abide by the following current good manufacturing practice (CGMP) regulations and recommendations regarding restriction of sick employees from production areas. 1) Any employee or worker in a production unit should be medically evaluated for infectious diseases such as COVID-19. 2) If any of individual is exhibiting COVID-19 symptoms, they shall be restricted from entering the production house premises of the company to prevent contamination of drugs and active pharmaceutical ingredients (API).

Thus, the COVID-19 pandemic has negatively affected the Global therapeutic protein and oral vaccine market.

 

Labels:

Comments

Post a Comment

Popular posts from this blog

Virology Testing Market Detailed In New Research Report 2023

  Virology testing consist of diagnostic methods that help in early detection of the disease such as hepatitis, influenza, HIV, sexually transmitted disease, RCV, and other viral associated disease. Virology testing examines for detection of viral antigens, nucleic acids, and antibodies in the given sample in order to confirm the presence of particular viral infection. There are more than 100 viral diseases identified. Virology Testing Market- Market Dynamics Virology testing market is projected to witness significant growth during forecast period with rising prevalence of virus originated diseases such as flu, hepatitis, AIDS, and STDs, Ebola, Influenza based viral infections, severe acute respiratory syndrome from coronavirus, hemorrhagic fever etc. across world. Early and fast diagnosis of virus infection is very essential to start treatment course. According to the World Health Organization (WHO), January 2018 factsheet, all types of influenza in combination causes annual...
Post a Comment
Read more

Epidermolysis Bullosa Therapeutics Market Is Booming Worldwide 2023-2028

  Epidermolysis bullosa is a group of rare inherited skin disorders that causes the skin to become very fragile. Any trauma or friction to the skin can cause painful blisters. The symptoms of epidermolysis bullosa include skin that blisters easily, blisters on hands and soles of the feet, thickened skin that may be scarred or change color over time, and thickening of the skin and nails. There are three types of epidermolysis bullosa which includes: ·          Epidermolysis bullosa simplex (EBS) – the most common type, which can range from mild, with a low risk of serious complications to severe ·          Dystrophic epidermolysis bullosa (DEB) – which can range from mild to severe ·          Junctional epidermolysis bullosa (JEB) – a rare form of epidermolysis bullosa that ranges from moderate to severe The type reflects where on the body the blistering ...
Post a Comment
Read more

Immobilized Trypsin Market continues to witness major growth due to extensive applications in protein identification, protein interactions, and protein characterization

  Immobilized Trypsin is the trade name for colloidal silver. This insoluble substance is synthesized as a result of the interaction of an acid (hydrogen) and an alkaline (monohydrate) base. Colloidal silver has numerous applications in the medical world. For instance, in veterinary science, Immobilized Silver compounds are often administered to tissues to stimulate their growth, as well as to prevent or reduce tissue damage caused by injuries and other external factors. Colloidal silver has also been found to have anti-bacterial, anti-viral, and anti-fungal properties. The clinical significance of these properties is still being studied; however, Immobilized Silver is widely used as a bacterial colloid, a degradable component of water softeners, and as a wound dressing ingredient in various fields of medicine. Trypsin is an amino acid that is found in proteins like albumin and gelatin. Trypsin belongs to the PA family of serines, present in the intestines of all vertebrates, in ...
Post a Comment
Read more